Who are Ultomiris's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AVACINCAPTAD PEGOL SODIUM, Veopoz, Izervay, Ro 205720, Eculizumab+IVMP, ULTOMIRIS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ravulizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ultomiris — Competitive Intelligence Brief

Ultomiris (RAVULIZUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement Inhibitor [EPC]. Area: Cardiovascular.

marketed Complement Inhibitor [EPC] Complement C5 Cardiovascular Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Ultomiris (RAVULIZUMAB) — AstraZeneca. Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ultomiris TARGET	RAVULIZUMAB	AstraZeneca	marketed	Complement Inhibitor [EPC]	Complement C5	2018-01-01
AVACINCAPTAD PEGOL SODIUM	AVACINCAPTAD PEGOL SODIUM		marketed	Complement Inhibitors	Complement C5	2023-01-01
Veopoz	POZELIMAB	Regeneron	marketed	Complement Inhibitor [EPC]	Complement C5	2023-01-01
Izervay	AVACINCAPTAD PEGOL	Astellas Pharma	marketed		Complement C5	2023-01-01
Ro 205720	CARPROFEN	Roche	marketed	carprofen	Complement C5, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1987-01-01
Eculizumab+IVMP	Eculizumab+IVMP	Chinese PLA General Hospital	marketed	Complement inhibitor + corticosteroid combination	Complement C5 + glucocorticoid receptor
ULTOMIRIS	RAVULIZUMAB-CWVZ	ALEXION PHARM	marketed		Complement C5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-11 — AVACINCAPTAD PEGOL SODIUM · 8236773 · Method of Use · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 9617546 · Compound · US
2027-02-14 — AVACINCAPTAD PEGOL SODIUM · 7579456 · Compound · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11491176 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 11273171 · Method of Use · US
2034-07-11 — AVACINCAPTAD PEGOL SODIUM · 12016875 · Method of Use · US

Sponsor landscape (Complement Inhibitor [EPC] class)

AstraZeneca · 2 drugs in this class
AMGEN INC · 1 drug in this class
REGENERON PHARMACEUTICALS · 1 drug in this class
Regeneron · 1 drug in this class
SAMSUNG BIOEPIS CO LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ultomiris — Competitive Intelligence Brief. https://druglandscape.com/ci/ravulizumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab